NASDAQ:BBNX

Beta Bionics (BBNX) Stock Price, News & Analysis

Beta Bionics logo
$13.35 -0.98 (-6.85%)
Closing price 03:59 PM Eastern
Extended Trading
$13.09 -0.26 (-1.91%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Beta Bionics Stock (NASDAQ:BBNX)

Advanced

Key Stats

Today's Range
$13.02
▼
$15.07
50-Day Range
$13.35
▼
$22.81
52-Week Range
$8.80
▼
$32.71
Volume
2.28 million shs
Average Volume
1.17 million shs
Market Capitalization
$725.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.69
Consensus Rating
Moderate Buy

Company Overview

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users.

The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings. The U.S. Food and Drug Administration cleared the system for use by people with type 1 diabetes ages six and older in 2023.

Founded by researcher Edward Damiano, Beta Bionics developed the iLet through a multiyear effort to advance automated diabetes management. Sean Saint has served as the company’s chief executive officer. The company focuses on the U.S. diabetes-care market.

AI Generated. May Contain Errors.

Beta Bionics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

BBNX MarketRank™: 
3.32375478927 of 5 stars

Beta Bionics scored higher than 66% of companies evaluated by MarketBeat, and ranked 198th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Beta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 9 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Beta Bionics has a consensus price target of $23.69, representing about 77.5% upside from its current price of $13.35.

  • Amount of Analyst Coverage

    Beta Bionics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Beta Bionics' stock forecast and price target.
  • Earnings Growth

    Earnings for Beta Bionics are expected to decrease in the coming year, from ($2.04) to ($2.11) per share.

  • Price to Book Value per Share Ratio

    Beta Bionics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.67% of the float of Beta Bionics has been sold short.
  • Short Interest Ratio / Days to Cover

    Beta Bionics has a short interest ratio ("days to cover") of 3.94, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Beta Bionics has recently decreased by 27.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Beta Bionics does not currently pay a dividend.

  • Dividend Growth

    Beta Bionics does not have a long track record of dividend growth.

  • News Sentiment

    Beta Bionics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Beta Bionics this week, compared to 8 articles on an average week.
  • Search Interest

    1 people have searched for BBNX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,026,928.00 in company stock.

  • Percentage Held by Insiders

    5.30% of the stock of Beta Bionics is held by insiders.

  • Percentage Held by Institutions

    Beta Bionics has minimal institutional ownership at this time.

  • Read more about Beta Bionics' insider trading history.
Receive BBNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BBNX Stock News Headlines

Beta Bionics (NASDAQ:BBNX) Insider Sells 775 Shares of Stock
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Headlines

BBNX Stock Analysis - Frequently Asked Questions

Beta Bionics' stock was trading at $30.47 at the beginning of the year. Since then, BBNX stock has decreased by 56.2% and is now trading at $13.3480.

Beta Bionics, Inc. (NASDAQ:BBNX) announced its quarterly earnings results on Tuesday, October, 27th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.01. The business earned $35.51 million during the quarter. Beta Bionics had a negative trailing twelve-month return on equity of 27.33% and a negative net margin of 65.31%.
Read the conference call transcript
.

Beta Bionics (BBNX) raised $198 million in an IPO on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $16.00-$17.00 per share.

Beta Bionics' top institutional shareholders include Soleus Capital Management L.P. (6.89%), State Street Corp (1.88%), Goldman Sachs Group Inc. (0.54%) and Jefferies Financial Group Inc. (0.17%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider, Mark Hopman, Adam Lezack and Christy Jones.
View institutional ownership trends
.

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
10/27/2026
Today
11/19/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BBNX
Previous Symbol
NASDAQ:BBNX
CIK
1674632
Fax
N/A
Employees
423
Year Founded
2015

Price Target and Rating

High Price Target
$30.00
Low Price Target
$16.00
Potential Upside/Downside
+77.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.20 million
Net Margins
-65.31%
Pretax Margin
-65.31%
Return on Equity
-27.33%
Return on Assets
-24.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.92
Quick Ratio
8.22

Sales & Book Value

Annual Sales
$100.25 million
Price / Sales
7.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.38 per share
Price / Book
1.81

Miscellaneous

Outstanding Shares
54,370,000
Free Float
51,486,000
Market Cap
$725.73 million
Optionable
Optionable
Beta
3.44

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:BBNX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners